Yoo, Hye Hyun Chung, Hye Jin Lee, Jaeick Lee, Chang-Seok Kang, Min Jung Kim, Dong-Hyun 2024-01-20T23:34:32Z 2024-01-20T23:34:32Z 2021-09-03 2008-03 0090-9556 https://pubs.kist.re.kr/handle/201004/133696 The in vitro metabolism of 1-[2-(5-tert-butyl-[1,3,4] oxadiazole-2-carbonyl)-4-fluoro-pyrrolidin-1-yl]-2-(2-hydroxy-1,1-dimethyl-ethylamino)-ethanone(LC15-0133), a novel dipeptidyl peptidase-4 inhibitor, was investigated using a hepatic microsomal system. The structures of the metabolites were characterized using mass spectral analysis and by comparison with synthetic references. The in vitro incubation of LC15-0133 with rat liver microsomes resulted in the formation of six metabolites, with the major metabolic reactions being hydroxylation and carbonyl reduction. Of the metabolites, a C-demethylated metabolite (M4) was identified, but was only detected in rat liver microsomes; experimental evidence revealed that the C-demethylated metabolite was generated by nonenzymatic decarboxylation of the carboxyl metabolite (M1). Nonenzymatic decarboxylation is postulated to occur due to the resonance stabilization by the oxadiazole ring attached to the tert-butyl moiety. English AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS IN-VITRO DPP-4 INHIBITORS O-DEALKYLATION METABOLISM TERFENADINE Enzymatic C-demethylation of 1-[2-(5-tert-butyl-[1,3,4]oxadiazole-2-carbonyl)-4-fluoro-pyrrolidin-1-y l]-2-(2-hydroxy-1,1-dimethyl-ethylamino)ethanone(LC15-0133) in rat liver microsomes Article 10.1124/dmd.107.019133 1 DRUG METABOLISM AND DISPOSITION, v.36, no.3, pp.485 - 489 DRUG METABOLISM AND DISPOSITION 36 3 485 489 scie scopus 000253445400003 2-s2.0-40849096097 Pharmacology & Pharmacy Pharmacology & Pharmacy Article IN-VITRO DPP-4 INHIBITORS O-DEALKYLATION METABOLISM TERFENADINE